| Charles Williams, PT | |
|
1501 E Fulton Ter, Suite 1, Garden City, KS 67846-6289 | |
| (620) 805-6883 | |
| (620) 805-6886 |
| Full Name | Charles Williams |
|---|---|
| Gender | Male |
| Speciality | Physical Therapy |
| Experience | 22 Years |
| Location | 1501 E Fulton Ter, Garden City, Kansas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1326129354 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | 11-03639 (Kansas) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Western Kansas Rehabilitation Services, Pa. | 6103065552 | 2 |
News Archive
United Cannabis Corporation today announced that it moved its provisional patent application to the next phase by filing a utility patent application related to the unique combinations of pharmaceutically active cannabinoids used to treat disorders of the nervous system, immune system and cancer with the U.S. Patent and Trademark Office.
Brachial plexus root avulsion is the most serious type of peripheral nerve injury. Valproic acid has been shown to exert neuroprotective effects and promote neurite outgrowth in several peripheral nerve injury models. However, whether valproic acid can exert its beneficial effect on neurons after brachial plexus avulsion injury is currently unknown.
Plexxikon Inc. announces that enrollment has been initiated and the first patient has been dosed in a pivotal Phase 3 trial of PLX4032 (RG7204) in patients with metastatic melanoma. PLX4032 is a novel, oral and highly targeted drug that is designed to inhibit the BRAF cancer-causing mutation that occurs in about 50 percent of melanomas and about eight percent of all solid tumors. The randomized, controlled, Phase 3 "BRAF Inhibitor in Melanoma" (BRIM3) trial in previously untreated patients is part of the planned registration program for PLX4032.
iBio, Inc. today announced it has acquired Orphan Drug Designation for plant-produced human alpha galactosidase A and related property rights from an affiliate of Kentucky Bioprocessing LLC and has initiated a program, based on its iBioLaunch platform, to develop an improved version of the enzyme for therapy of Fabry disease.
Cancer risk increases with age, and scientists have long perceived a possible evolutionary tradeoff between longer lifespan and greater risk of cancer. Now, researchers at Fox Chase Cancer Center find direct evidence for that tradeoff in new data showing that expression of a key tumor suppressor protein induces premature aging in mice.
› Verified 3 days ago
| Provider Name | Western Kansas Rehabilitation Services, Pa. |
|---|---|
| Provider Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Provider Identifiers | NPI Number: 1962746826 PECOS PAC ID: 6103065552 Enrollment ID: O20130617000320 |
News Archive
United Cannabis Corporation today announced that it moved its provisional patent application to the next phase by filing a utility patent application related to the unique combinations of pharmaceutically active cannabinoids used to treat disorders of the nervous system, immune system and cancer with the U.S. Patent and Trademark Office.
Brachial plexus root avulsion is the most serious type of peripheral nerve injury. Valproic acid has been shown to exert neuroprotective effects and promote neurite outgrowth in several peripheral nerve injury models. However, whether valproic acid can exert its beneficial effect on neurons after brachial plexus avulsion injury is currently unknown.
Plexxikon Inc. announces that enrollment has been initiated and the first patient has been dosed in a pivotal Phase 3 trial of PLX4032 (RG7204) in patients with metastatic melanoma. PLX4032 is a novel, oral and highly targeted drug that is designed to inhibit the BRAF cancer-causing mutation that occurs in about 50 percent of melanomas and about eight percent of all solid tumors. The randomized, controlled, Phase 3 "BRAF Inhibitor in Melanoma" (BRIM3) trial in previously untreated patients is part of the planned registration program for PLX4032.
iBio, Inc. today announced it has acquired Orphan Drug Designation for plant-produced human alpha galactosidase A and related property rights from an affiliate of Kentucky Bioprocessing LLC and has initiated a program, based on its iBioLaunch platform, to develop an improved version of the enzyme for therapy of Fabry disease.
Cancer risk increases with age, and scientists have long perceived a possible evolutionary tradeoff between longer lifespan and greater risk of cancer. Now, researchers at Fox Chase Cancer Center find direct evidence for that tradeoff in new data showing that expression of a key tumor suppressor protein induces premature aging in mice.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Charles Williams, PT 1901 Grandview Dr E, Garden City, KS 67846-8324 Ph: (620) 271-0957 | Charles Williams, PT 1501 E Fulton Ter, Suite 1, Garden City, KS 67846-6289 Ph: (620) 805-6883 |
News Archive
United Cannabis Corporation today announced that it moved its provisional patent application to the next phase by filing a utility patent application related to the unique combinations of pharmaceutically active cannabinoids used to treat disorders of the nervous system, immune system and cancer with the U.S. Patent and Trademark Office.
Brachial plexus root avulsion is the most serious type of peripheral nerve injury. Valproic acid has been shown to exert neuroprotective effects and promote neurite outgrowth in several peripheral nerve injury models. However, whether valproic acid can exert its beneficial effect on neurons after brachial plexus avulsion injury is currently unknown.
Plexxikon Inc. announces that enrollment has been initiated and the first patient has been dosed in a pivotal Phase 3 trial of PLX4032 (RG7204) in patients with metastatic melanoma. PLX4032 is a novel, oral and highly targeted drug that is designed to inhibit the BRAF cancer-causing mutation that occurs in about 50 percent of melanomas and about eight percent of all solid tumors. The randomized, controlled, Phase 3 "BRAF Inhibitor in Melanoma" (BRIM3) trial in previously untreated patients is part of the planned registration program for PLX4032.
iBio, Inc. today announced it has acquired Orphan Drug Designation for plant-produced human alpha galactosidase A and related property rights from an affiliate of Kentucky Bioprocessing LLC and has initiated a program, based on its iBioLaunch platform, to develop an improved version of the enzyme for therapy of Fabry disease.
Cancer risk increases with age, and scientists have long perceived a possible evolutionary tradeoff between longer lifespan and greater risk of cancer. Now, researchers at Fox Chase Cancer Center find direct evidence for that tradeoff in new data showing that expression of a key tumor suppressor protein induces premature aging in mice.
› Verified 3 days ago
Liana Colson, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 714 Ballinger St, Garden City, KS 67846 Phone: 620-275-0291 | |
Kylie Horelica, Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 401 E Spruce St, Garden City, KS 67846 Phone: 620-272-2222 | |
St. Catherine Hospital - Garden City Rehab Unit Physical Therapist Medicare: Medicare Enrolled Practice Location: 401 E Spruce St, Garden City, KS 67846 Phone: 620-272-2222 Fax: 620-272-2127 | |
Mr. Zachariah O Stuke, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 1800 Palace Dr, Suite C, Garden City, KS 67846 Phone: 620-271-0700 Fax: 620-271-0703 | |
Dr. Katherine Nicole Navarro, PT, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 101 E Fulton St, Garden City, KS 67846 Phone: 620-275-8400 | |
Living At Home Llc Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 13610 N Mennonite Rd, Garden City, KS 67846 Phone: 620-271-8674 |